CYP4F12 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4269299	1.00	2/20
SCHEMBL4269302	1.00	2/20
SCHEMBL5970916	0.55	2/20
SCHEMBL5665730	0.41	2/20
SCHEMBL5665735	0.41	2/20
SCHEMBL13060909	0.40	2/20
SCHEMBL14264483	0.40	2/20
SCHEMBL5679276	0.39	2/20
SCHEMBL5679282	0.39	2/20
SCHEMBL16798246	0.37	2/20
SCHEMBL18012065	0.36	2/20
SCHEMBL18430941	0.36	2/20
SCHEMBL16079472	0.64	1/20
SCHEMBL11158755	0.62	1/20
SCHEMBL6814131	0.61	1/20
SCHEMBL6819737	0.61	1/20
SCHEMBL9724438	0.61	1/20
SCHEMBL765000	0.61	1/20
SCHEMBL765847	0.61	1/20
SCHEMBL10289874	0.61	1/20

Clinical trials — most relevant to CYP4F12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
OPTImization of the Dose of tacroliMUS by Bayesian Prediction	PHASE4	COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma	PHASE1	COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors	PHASE1	UNKNOWN
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Drug-Drug Interaction (DDI) Study in Healthy Volunteers	PHASE1	COMPLETED
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone	PHASE1	UNKNOWN
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
The Study of Warfarin Maintenance Dose in Chinese Patients	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Pharmacogenetic Dosage Algorithm for Acenocoumarol	nan	COMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney	nan	UNKNOWN
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients	nan	COMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	nan	COMPLETED
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP4F12 binder may also engage these)

Protein	Name	Similarity
Q9EP75	—	1.000	Q9EP75 →
P51870	—	1.000	P51870 →
P51869	—	1.000	P51869 →
CYP4F2	Cytochrome P450 4F2	0.999	landscape →
P51871	—	0.998	P51871 →
CYP4F3	Cytochrome P450 4F3	0.998	landscape →
Q99N16	—	0.996	Q99N16 →
Q3MID2	—	0.995	Q3MID2 →
P33274	—	0.994	P33274 →
Q6NT55	—	0.993	Q6NT55 →
CYP4F8	Cytochrome P450 4F8	0.992	landscape →
Q9GLL1	—	0.992	Q9GLL1 →
Q9W011	—	0.991	Q9W011 →
Q6ZWL3	—	0.989	Q6ZWL3 →
P15129	—	0.988	P15129 →
CYP4X1	Cytochrome P450 4X1	0.987	landscape →
Q5RCN6	—	0.987	Q5RCN6 →
Q9VLZ7	—	0.987	Q9VLZ7 →
CYP4F11	Cytochrome P450 4F11	0.986	landscape →
CYP4Z1	Cytochrome P450 4Z1	0.986	landscape →
Q9VXY0	—	0.986	Q9VXY0 →
A2RRT9	—	0.985	A2RRT9 →
Q9V7G5	—	0.985	Q9V7G5 →
Q9DBW0	—	0.985	Q9DBW0 →
Q9VYY4	—	0.984	Q9VYY4 →
O46054	—	0.983	O46054 →
P15128	—	0.983	P15128 →
Q9VVN6	—	0.982	Q9VVN6 →
Q9VGB3	—	0.982	Q9VGB3 →
Q8K4D6	—	0.982	Q8K4D6 →